BACK TO ALL STUDIES

Phase 3 of AZD1222 (a Non-Replicating ChAdOx1 Vector Vaccine) for the Prevention of COVID-19

PRIMARY OBJECTIVE(s)

1. To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults ≥ 18 years of age. 2. To assess the safety and tolerability of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age.3. To assess the reactogenicity of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age.

PRINCIPAL INVESTIGATOR(S)

Emmanuel Walter, MD

CONTACT
Emily Randolph
emily.randolph@duke.edu
TREATMENT/CLINICAL & LAB INVESTIGATION

Clinical and Laboratory Investigation

POPULATION
Adults ≥ 18 years of age.
FULL NAME OF DIAGNOSTIC TEST
Lab Used for Diagnostic Test
Full Name of Serology/Antibody Test
Lab Used for Serology/Antibody Test
Want more information about this study?
study website